19 June 2013
Keywords: gsk, rls, drug, well-tolerated, uk, major, glaxosmithkline
Article | 28 April 2008
UK drug major GlaxoSmithKline says that data from the first pivotal study of XP13512/GSK1838262, a sustained-release investigational agent
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
28 April 2008
© 2013 thepharmaletter.com